Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18764298 | BIO-BASED EPOXY CHAIN EXTENDER AND PREPARATION METHOD THEREOF | July 2024 | January 2025 | Allow | 7 | 2 | 0 | No | No |
| 18657122 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | May 2024 | July 2025 | Allow | 14 | 1 | 0 | No | No |
| 18426035 | NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMA | January 2024 | June 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18402325 | CROWN ETHER CARBENES AND METHODS OF USE | January 2024 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18390071 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | December 2023 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18524339 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | November 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18513752 | GLP-1 Receptor Agonists and Uses Thereof | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18384698 | 4,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18383683 | 4-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18379724 | 4-NITRO-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | December 2023 | Allow | 2 | 0 | 0 | No | No |
| 18475749 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18373241 | METHODS FOR CONVERTING CBD TO TETRAHYDROCANNABINOLS | September 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18242305 | CROWN ETHER AMINES AND METHODS OF USE | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18456819 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | August 2023 | May 2025 | Allow | 20 | 2 | 1 | No | No |
| 18448696 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | August 2023 | August 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18363585 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | August 2023 | November 2024 | Allow | 16 | 2 | 0 | No | No |
| 18228192 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | July 2023 | June 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18226767 | PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME | July 2023 | December 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18351472 | CRYSTALS | July 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18269109 | SYSTEM AND METHOD FOR PREPARING EPOXY CHLOROPROPANE | June 2023 | July 2024 | Allow | 12 | 1 | 0 | No | No |
| 18320906 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | May 2023 | September 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18316579 | TETRACYCLIC COMPOUNDS AND USES THEREOF | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18299442 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | April 2023 | December 2024 | Allow | 20 | 2 | 1 | No | No |
| 18194155 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | March 2023 | January 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18110416 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | February 2023 | February 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18161603 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | January 2023 | November 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 18158006 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | January 2023 | February 2025 | Allow | 24 | 2 | 1 | No | No |
| 18093773 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | January 2023 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 18147189 | NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMA | December 2022 | October 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 18066000 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | December 2022 | May 2025 | Allow | 29 | 1 | 0 | No | No |
| 18063331 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | December 2022 | July 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18073728 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18070408 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | November 2022 | April 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17985415 | LIGANDS TO CEREBLON (CRBN) | November 2022 | June 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 17982983 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | November 2022 | August 2023 | Allow | 10 | 0 | 0 | No | No |
| 17981695 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | November 2022 | December 2023 | Allow | 14 | 1 | 0 | No | No |
| 17981201 | CROWN ETHER CARBENES AND METHODS OF USE | November 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17981162 | CROWN ETHER AMINES AND METHODS OF USE | November 2022 | June 2023 | Allow | 7 | 0 | 0 | No | No |
| 17922999 | CO-CRYSTAL OF KETOPROFEN, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | November 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 17967599 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | October 2022 | February 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18046205 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | October 2022 | April 2024 | Allow | 18 | 1 | 0 | No | No |
| 17963823 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | October 2022 | November 2024 | Allow | 25 | 1 | 1 | No | No |
| 17950772 | METHODS AND COMPOSITIONS FOR TERPENOID TRICYCLOALKANE SYNTHESIS | September 2022 | January 2025 | Allow | 28 | 5 | 1 | No | No |
| 17946908 | Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof | September 2022 | April 2025 | Allow | 31 | 1 | 1 | No | No |
| 17931773 | Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof | September 2022 | March 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17940287 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | September 2022 | August 2024 | Allow | 23 | 2 | 0 | No | No |
| 17905799 | COMPOUND PRODUCING METHOD, AND COMPOUND | September 2022 | February 2023 | Allow | 5 | 0 | 0 | No | No |
| 17902618 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | September 2022 | April 2024 | Allow | 20 | 2 | 0 | No | No |
| 17820845 | CANNABIS SPECIES AS INDUSTRIAL CHEMICAL FEEDSTOCKS | August 2022 | January 2025 | Abandon | 29 | 4 | 1 | No | No |
| 17819089 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | August 2022 | November 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17816349 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | July 2022 | January 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 17841570 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17750220 | PYRROLIDINE DERIVATIVES | May 2022 | July 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17743534 | PROCESS FOR PREPARING ESTERS OF N-ACYLATED AMINO ACIDS WITH ACID-LABILE KETO PROTECTIVE GROUP FUNCTIONS | May 2022 | November 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17744470 | CATIONIC ANTIMICROBIAL OLIGO-GUANIDINIUM DENDRIMERS AND COMPOSITIONS | May 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17732659 | Cannabidiol (CBD) as Chemical for Treating Aging-related Degenerative Diseases and Promoting Health Aging | April 2022 | February 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17713221 | GLYCOPYRROLATE SALTS | April 2022 | September 2023 | Allow | 18 | 2 | 0 | No | No |
| 17701404 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | March 2022 | May 2023 | Allow | 14 | 1 | 0 | No | No |
| 17692113 | ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDS | March 2022 | January 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17679659 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | February 2022 | January 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17587268 | NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE | January 2022 | February 2024 | Allow | 25 | 2 | 1 | No | No |
| 17574820 | NLRP3 INFLAMMASOME INHIBITORS | January 2022 | March 2024 | Allow | 26 | 1 | 0 | No | No |
| 17570420 | METHOD FOR PRODUCING FISETIN OR FISETIN DERIVATIVES | January 2022 | November 2022 | Allow | 10 | 0 | 0 | No | No |
| 17566248 | ATYPICAL COUPLING METHOD FOR THE PREPARATION OF 1,2-DI(THIOPHEN-2-YL)ETHENE-1,2-DIOL COMPOUNDS VIA A CU(II) CATALYST | December 2021 | April 2023 | Allow | 15 | 1 | 0 | No | No |
| 17564079 | COMPOSITIONS OF BIOLOGICALLY ACTIVE MENAQUINOL DERIVATIVES AND METHODS OF TREATMENT | December 2021 | April 2024 | Allow | 27 | 2 | 0 | No | No |
| 17623205 | NEUROKININ-1 ANTAGONIST | December 2021 | May 2025 | Allow | 41 | 1 | 0 | No | No |
| 17541682 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | December 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17536383 | PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE | November 2021 | May 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17527833 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | November 2021 | June 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17526742 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | November 2021 | July 2023 | Allow | 20 | 2 | 0 | No | No |
| 17517166 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | November 2021 | December 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17495447 | BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASES | October 2021 | December 2022 | Allow | 14 | 0 | 0 | No | No |
| 17492469 | METHOD FOR TREATING DENGUE VIRUS INFECTION | October 2021 | April 2025 | Allow | 42 | 4 | 0 | Yes | No |
| 17448508 | INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR | September 2021 | December 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17476261 | Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof | September 2021 | August 2022 | Allow | 11 | 2 | 1 | No | No |
| 17472016 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | September 2021 | November 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17462155 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | August 2021 | October 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17460922 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | August 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17460061 | CRYSTALS | August 2021 | March 2023 | Allow | 19 | 1 | 0 | No | No |
| 17408458 | CANNABIS FARMING METHODS | August 2021 | May 2025 | Abandon | 44 | 3 | 1 | Yes | No |
| 17445057 | CYCLOPHANE-SUSTAINED HIGH PERFORMANCE PORPHYRINS | August 2021 | May 2024 | Allow | 33 | 2 | 1 | No | No |
| 17391202 | COMPOSITION CONTAINING AN ALK5 INHIBITOR, EW-7197 | August 2021 | August 2024 | Abandon | 37 | 4 | 0 | No | No |
| 17381441 | Cannabinoid Compositions and Methods for Treating Joint Pain and Inflammation | July 2021 | August 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17424220 | METHODS FOR ENANTIOSELECTIVE PREPARATION OF CHIRAL TETRAARYLMETHANES | July 2021 | March 2025 | Allow | 44 | 2 | 0 | No | No |
| 17422587 | COMPOSITION FOR COMPETITIVE INHIBITION OF OREXIN RECEPTORS | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17419930 | AN EFFICIENT AND ENVIRONMENT FRIENDLY PROCESS FOR CHLOROMETHYLATION OF SUBSTITUTED BENZENES | June 2021 | March 2022 | Allow | 8 | 0 | 0 | No | No |
| 17360315 | METHODS OF SYNTHESIZING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE | June 2021 | May 2023 | Allow | 22 | 1 | 0 | No | No |
| 17359424 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | June 2021 | June 2024 | Allow | 36 | 2 | 1 | No | No |
| 17356756 | COVALENT FUNCTIONALIZATION OF CARBON NANOTUBES GROWN ON A SURFACE | June 2021 | January 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17353567 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | June 2021 | July 2023 | Allow | 25 | 1 | 1 | No | No |
| 17349998 | AI ASSISTED CYCLIC CARBONATE MONOMER SYNTHESIS | June 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17337615 | 2-(4-chloro-2,6-dimethyl-phenyl)propanedinitrile | June 2021 | February 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17328531 | METHODS OF SYNTHESIS FOR A THIOKETAL DIOL | May 2021 | January 2023 | Allow | 20 | 2 | 0 | Yes | No |
| 17320286 | FARNESOID X RECEPTOR MODULATORS | May 2021 | December 2024 | Allow | 44 | 2 | 1 | No | No |
| 17292249 | METHOD FOR PRODUCING CARBONATE DERIVATIVE | May 2021 | April 2025 | Allow | 47 | 1 | 0 | Yes | No |
| 17307905 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS AGAINST HIV/AIDS | May 2021 | February 2022 | Allow | 9 | 1 | 0 | No | No |
| 17245235 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | April 2021 | August 2023 | Allow | 28 | 2 | 0 | No | No |
| 17285785 | CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | April 2021 | January 2024 | Allow | 33 | 3 | 1 | No | No |
| 17285443 | METHODS FOR EXTRACTION, PROCESSING, AND PURIFICATION OF A SELECTED FAMILY OF TARGET COMPOUNDS FROM CANNABIS | April 2021 | September 2021 | Allow | 5 | 1 | 0 | No | No |
| 17217599 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | March 2021 | November 2022 | Abandon | 20 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUGHLIN, MATTHEW P.
With a 55.6% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COUGHLIN, MATTHEW P works in Art Unit 1626 and has examined 1,279 patent applications in our dataset. With an allowance rate of 71.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner COUGHLIN, MATTHEW P's allowance rate of 71.1% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by COUGHLIN, MATTHEW P receive 1.64 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by COUGHLIN, MATTHEW P is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +14.3% benefit to allowance rate for applications examined by COUGHLIN, MATTHEW P. This interview benefit is in the 57% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.2% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.1% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 71.0% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 77.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 59.5% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 6.5% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.